Меню
Идёт набор NCT05229679

HPV-based Screening Among Women 23-29 Years of Age

Без фазы С лечением Human Papilloma Virus Cervical Intraepithelial Neoplasia Cervical Cancer

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают
В протоколе указаны: HPV testing.
Кому может быть актуально
Состояния в реестре: Human Papilloma Virus, Cervical Intraepithelial Neoplasia, Cervical Cancer. Базовые параметры: 23 лет — 29 лет · Женщины.
Что важно проверить
Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится
Швеция
Следующий шаг
Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Официальное название

Evaluation of Organized Human Papilloma Virus (HPV) Screening of 23-29-year-old Women

Обзор

The aim of the trial is to determine whether organized screening with primary HPV analysis provide higher cancer protection in the age group 23-29 years compared to primary cytology.

Подробное описание

The aim is to investigate whether primary HPV analysis in the organized cell sampling program for women in the age group 23-29 provides higher cancer protection compared to the current method where cell samples are primarily analyzed with cytology. In this study, all women in the age group 23-29 in the Stockholm and Skåne Region of Sweden will participate. Age is defined by year of birth. For 2020, women born 1991-1997 are included. Sampling and collection of samples is the same as for cytology.

Вмешательства

  • Диагностический тест HPV testing
    All women age 23-29 resident in the pilot counties will be invited to HPV screening as of the study start date. The same invitation as currently used for women aged 30 and upwards will be used. This information clearly states that it is possible to opt out of the program and that data from the screening program will be collected to regional and national quality registers who will systematically evaluate the quality of the care. At the screening station, the samples are collected identically rega

Первичные конечные точки

  • Incidence of cervical cancer [Срок оценки: Measured once during 1 year, year 1.]
  • Incidence of cervical cancer [Срок оценки: Measured once during 1 year, year 2.]
  • Incidence of cervical cancer [Срок оценки: Measured once during 1 year, year 3.]
  • Incidence of cervical cancer [Срок оценки: Measured once during 1 year, year 4.]
  • Incidence of cervical cancer [Срок оценки: Measured once during 1 year, year 5.]
  • Incidence of cervical cancer [Срок оценки: Measured once during 1 year, year 6.]
  • Incidence of cervical cancer [Срок оценки: Measured once during 1 year, year 7.]
  • Incidence of cervical cancer [Срок оценки: Measured once during 1 year, year 8.]
  • Incidence of cervical cancer [Срок оценки: Measured once during 1 year, year 9.]
  • Incidence of cervical cancer [Срок оценки: Measured once during 1 year, year 10.]
Вторичные конечные точки (10)
  • Cost-effectiveness of the new screening method [Срок оценки: Measured once during 1 year, year 1.]
  • Cost-effectiveness of the new screening method [Срок оценки: Measured once during 1 year, year 2.]
  • Cost-effectiveness of the new screening method [Срок оценки: Measured once during 1 year, year 3.]
  • Cost-effectiveness of the new screening method [Срок оценки: Measured once during 1 year, year 4.]
  • Cost-effectiveness of the new screening method [Срок оценки: Measured once during 1 year, year 5.]
  • Cost-effectiveness of the new screening method [Срок оценки: Measured once during 1 year, year 6.]
  • Cost-effectiveness of the new screening method [Срок оценки: Measured once during 1 year, year 7.]
  • Cost-effectiveness of the new screening method [Срок оценки: Measured once during 1 year, year 8.]
  • Cost-effectiveness of the new screening method [Срок оценки: Measured once during 1 year, year 9.]
  • Cost-effectiveness of the new screening method [Срок оценки: Measured once during 1 year, year 10.]

Критерии участия

Критерии включения

  • Women ages 23-29 invited to screening.

Критерии исключения

  • Women who do not show up for screening or do not consent.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение
Не применимо
Модель
Одна группа
Маскирование
Открытое
Основная цель
Профилактика

Центры проведения

Швеция · 2 центра
  • Region of Skåne — Lund
  • Region Stockholm — Stockholm

Идентификаторы

NCT: NCT05229679 · 2020-00053

Первоисточники (государственные реестры)

Открыть это исследование на ClinicalTrials.gov ↗